A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) (NCT04544436)
A Phase IIIb Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.
Who can join: Review the eligibility criteria below.
Location: North Central Neurology Associates — Cullman, Alabama
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (120 Sites)
Showing the first 25 of 120 sites.
- North Central Neurology Associates — Cullman, Alabama
- Alabama Neurology Associates — Homewood, Alabama
- 21st Century Neurology — Phoenix, Arizona
- Profound Research, LLC — Carlsbad, California
- Stanford University Medical Center — Stanford, California
- Advanced Neurology of Colorado, LLC — Fort Collins, Colorado
- Neurology Associates, PA — Maitland, Florida
- University of South Florida — Tampa, Florida
- American Health Network Institute, LLC — Avon, Indiana
- University of Kansas Medical Center — Kansas City, Kansas
- The NeuroMedical Clinic of Central Louisiana — Alexandria, Louisiana
- Maine Medical Center — Scarborough, Maine
- Dragonfly Research, LLC — Wellesley, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- Washington University School of Medicine — St Louis, Missouri
- Cleveland Clinic Lou Ruvo — Las Vegas, Nevada
- Dent Neurological Institute — Amherst, New York
- UC Health Neurology — Dayton, Ohio
- Oklahoma Medical Research Foundation — Oklahoma City, Oklahoma
- Abington Neurological Associates — Willow Grove, Pennsylvania
- Tri-State Mountain Neurology — Johnson City, Tennessee
- Hope Neurology — Knoxville, Tennessee
- Bhupesh Dihenia M.D. P.A. — Lubbock, Texas
- Lone Star Neurology of San Antonio — San Antonio, Texas
- Evergreen MS Center — Kirkland, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis — Birmingham, Alabama
- MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience — New Orleans, Louisiana
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Phoenix, Arizona
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Carlsbad, California
- The Synergistic Effects of AIH and FES in Persons With MS — Chicago, Illinois
- A Health Action Process Approach Online Intervention for People With Multiple Sclerosis — Champaign, Illinois
Explore by condition: All Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.